Lenalidomide and subsequent TP53-mutated myeloid neoplasms, abnormal uterine bleeding after VTE, and novel tri-specific antibody for B-ALL
Blood Podcast
00:00
Optimized CD19-CD22 and CD3 Tri-Special Antibody in B-Cell Malignancies
Tri-specific antibody was initially developed in the context of B-cell malignancies. Antibody optimizes geometry of immunological synapses that form between tumor cells and T-cells. Tri-specific antibody showed similar binding and cytotoxicity as compared to bi-specific antibodies on cell lines expressing a single target.
Transcript
Play full episode
